Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients.
Tampellini M, Berruti A, Bitossi R, Gorzegno G, Alabiso I, Bottini A, Farris A, Donadio M, Sarobba MG, Manzin E, Durando A, Defabiani E, De Matteis A, Ardine M, Castiglione F, Danese S, Bertone E, Alabiso O, Massobrio M, Dogliotti L. Tampellini M, et al. Breast Cancer Res Treat. 2006 Aug;98(3):241-8. doi: 10.1007/s10549-005-9155-y. Epub 2006 May 3. Breast Cancer Res Treat. 2006. PMID: 16670941
Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival.
Berruti A, Zola P, Buniva T, Baù MG, Farris A, Sarobba MG, Bottini A, Tampellini M, Durando A, Destefanis M, Monzeglio C, Moro G, Sussio M, Perroni D, Dogliotti L. Berruti A, et al. Among authors: tampellini m. Anticancer Res. 1997 Jul-Aug;17(4A):2763-8. Anticancer Res. 1997. PMID: 9252712 Clinical Trial.
Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse.
Tampellini M, Berruti A, Gorzegno G, Bitossi R, Bottini A, Durando A, De Matteis A, Farris A, Donadio M, De Fabiani E, Manzin E, Arese P, Sarobba MG, Castiglione F, Moro G, Bonazzi G, Nuzzo F, Massobrio M, Dogliotti L. Tampellini M, et al. Tumour Biol. 2001 Nov-Dec;22(6):367-73. doi: 10.1159/000050639. Tumour Biol. 2001. PMID: 11786730
The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients.
Tampellini M, Saini A, Alabiso I, Bitossi R, Brizzi MP, Sculli CM, Berruti A, Gorzegno G, Magnino A, Sperti E, Miraglia S, Forti L, Alabiso O, Aglietta M, Harris A, Dogliotti L. Tampellini M, et al. Br J Cancer. 2006 Jul 3;95(1):13-20. doi: 10.1038/sj.bjc.6603204. Epub 2006 Jun 13. Br J Cancer. 2006. PMID: 16773070 Free PMC article. Clinical Trial.
Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease.
Tucci M, Mosca A, Lamanna G, Porpiglia F, Terzolo M, Vana F, Cracco C, Russo L, Gorzegno G, Tampellini M, Torta M, Reimondo G, Poggio M, Scarpa RM, Angeli A, Dogliotti L, Berruti A. Tucci M, et al. Among authors: tampellini m. Prostate Cancer Prostatic Dis. 2009;12(1):94-9. doi: 10.1038/pcan.2008.10. Epub 2008 Mar 11. Prostate Cancer Prostatic Dis. 2009. PMID: 18332901 Free article.
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
Generali D, Dovio A, Tampellini M, Tucci M, Tedoldi S, Torta M, Bonardi S, Allevi G, Aguggini S, Milani M, Harris AL, Bottini A, Dogliotti L, Angeli A, Berruti A. Generali D, et al. Among authors: tampellini m. Br J Cancer. 2008 Jun 3;98(11):1753-8. doi: 10.1038/sj.bjc.6604390. Epub 2008 May 27. Br J Cancer. 2008. PMID: 18506177 Free PMC article. Clinical Trial.
91 results